Find Clinical Trials

Inclusion Criteria 1. female and male participants 18 years or older and willing to provide Informed Consent 2. clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization)) 3. Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device 4. Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1 5. Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel) 6. clearance to participate in the study by the patient's medical oncologist 7. normal bone marrow function 8. able to read/complete study forms/assessments and understand instructions in English Exclusion criteria: a) Any physical condition which hinders the ability to safely participate in exercise including: uncontrolled or symptomatic cardiac/respiratory disease (e.g. uncontrolled angina, unusual shortness of breath, congestive heart failure, symptomatic peripheral vascular disease), stroke/myocardial infarction in the past year, fragility fracture, recent or planned orthopedic surgery, or any comorbid condition precluding exercise per the treating physician b) receipt of medications known to influence immune function including corticosteroids (\>10 mg prednisone equivalent), other immune-suppressive medication, or beta blockers47 c) Any infection or vaccination within the last 4 weeks d) e) Known HIV-positive participants on combination antiretroviral therapy f) concurrent participation in a therapeutic clinical trial or other exercise program g) pregnant h) medically advised to not exercise i) Unable to walk on a motor-driven treadmill for \~30 minutes at study enrollment j) Adults unable to consent k) No external catheters/drains (e.g., nephrostomy tube, foley catheter). A colostomy or Ileostomy is acceptable. l) Prior or concurrent non-breast malignancy. Those with prior cancers treated with curative intent are eligible. Participants with known (or history) of hepatitis B positive, or hepatitis C positive infection

Inclusion Criteria: * Diagnosed with type 2 diabetes (5.7% \< HbA1c \< 9.0%) * Not regularly physically active (150 mins moderate-vigorous physical activity per week) Exclusion Criteria: * Musculoskeletal issues preventing exercise training * Unstable medications over the last 3 months * Absolute contraindications to BFR (i.e. peripheral vascular disease) * A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions * A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) * Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely * Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity

Inclusion Criteria: * Healthy adults aged 19 years or older at the time of screening. * Body mass index (BMI) between 18 and 30 kg/m². * Male subjects: body weight ≥ 50 kg. * Female subjects: body weight ≥ 45 kg. * Clinically healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory test results, as determined by the investigator. * Willing and able to provide written informed consent after receiving a full explanation of the study. * Subjects (and their partners, if applicable) agree to use highly effective, non-hormonal contraception from the first dosing day until one week after the last dose. Exclusion Criteria: * Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing. * Participation in any clinical trial involving investigational products within 6 months prior to the first dose. * Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose. * History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair). * Known hypersensitivity to the investigational product or its components. * Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria. * History of clinically significant psychiatric illness. * Pregnant or breastfeeding women, or women with a possibility of pregnancy.

Inclusion Criteria: * Patient and care partner both aged ≥ 18 years * Patient with care partner (known person providing regular health-related, socioemotional, or practical support) willing to participate * Patient reporting depression symptoms on a screening tool (Patient Health Questionnaire) Exclusion Criteria: * Patient intended length of nursing facility stay \< 7 days * Patient evidencing more than mild impairment on a cognitive screen (Brief Interview for Mental Status) * Patient's roommate in skilled nursing facility already enrolled in study/intervention * Either patient or care partner reporting high risk of suicidality, based on a standardized safety assessment tool * Either patient or care partner participating in newly initiated psychotherapy

Inclusion Criteria: * Adult female or male participant - All genders (≥18 years old) * Diagnosis of CKD associated with T2D based on assessment by physician * Treatment according to local marketing authorization, finerenone 20 or 10 mg. Treatment should have been started up to 8 weeks before or after the ICF is signed. * Decision to initiate treatment with finerenone must be made before ICF is signed Exclusion Criteria: * Participation in an investigational trial at any time during the course of this study * Contra-indications according to the local label

Inclusion Criteria: 1. Is aged ≥2 years old at time of screening. 2. Has a clinical diagnosis of Type 1 or Type 2 diabetes for ≥ 6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis. 3. Is on MiniMed™ 780G with Simplera Sync sensor for at least 3 months before screening. 4. Has a glycosylated hemoglobin (HbA1c) \<11% (97 mmol/mol) at time of screening visit as processed at Point of Care (PoC) or local lab. 5. Must have a minimum daily insulin requirement (Total Daily Dose) of ≥ 6 units and a maximum of 250 units 6. Willing to switch to approved insulin per insulin pump labeling. 7. Investigator has confidence that the subject, parent(s)/legal guardian(s) can successfully operate all study devices and is capable of adhering to study visit schedule per protocol. 8. Subject, Parent(s)/legal guardian(s) is willing to participate in all training sessions as directed by study staff. 9. Subject, Parent(s)/legal guardian(s) is willing and able to provide written informed consent. 10. For subject with Type 2 Diabetes only: Is on stable dose of anti-diabetic medication (other than insulin) (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists/mimetics, metformin, SGLT2 inhibitors) for the last 3 months prior to screening. NB: Subject should not change type or dose of medication during the course of the study. 11. For Israel only: Subject, Parents(s)/legal guardian(s) is fluent in English. Exclusion Criteria: 1. Has Addison's disease, growth hormone deficiency, hypopituitarism or definite gastroparesis, uncontrolled coeliac disease, uncontrolled thyroid disorder, or poorly controlled asthma, per investigator judgment. 2. For subjects with Type 1 Diabetes only: Is using any anti-diabetic medication other than insulin 6 months before screening or plan on using during the study (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists/mimetics, metformin, SGLT2 inhibitors). 3. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any chronically oral, injectable, or IV glucocorticoids during the course of the study, per investigator judgement 4. Has had renal failure defined by creatinine clearance \<30 ml/min, as assessed by local lab test ≤ 6 months before screening or performed at screening at local lab, as defined by the creatinine-based Cockcroft, CKD-EPI or MDRD equations. 5. Has active or severe retinopathy in the last 6 months before screening 6. Has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection). 7. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment. 8. History of 2 or more DKA events in the last 3 months before screening. 9. Has had Hyperosmolar Hyperglycemic State (HHS) in the last 6 months before screening. 10. Is using hydroxyurea at time of screening or plans to use it during the study 11. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study. 12. Women who are breastfeeding. 13. Is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before screening, as per investigator judgment. 14. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment. 15. Subject, Parent(s)/legal guardian(s) are part of research staff involved with the study. 16. Subject, Parent(s)/legal guardian (s) are legally incompetent, illiterate, or vulnerable.

Inclusion Criteria: 1. Participant must be ≥ 18 years (and above legal age) at the time of screening. 2. Inoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-positive (either ER and/or PgR positive \[ER or PgR ≥ 1%\]) and HER2 IHC 0 (defined as including HER2 null with no staining or incomplete and faint/barely perceptible membrane staining in ≤ 10% of tumour cells) based on a fresh, or recent tissue sample obtained no more than 6 weeks prior to or during the screening period. 3. Progressed on and not suitable for further endocrine therapy per investigator assessment. 4. ECOG performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to the first dose of study intervention. 5. Minimum life expectancy of 12 weeks at screening. 6. Provision of acceptable tumour sample (newly acquired tumour biopsy at baseline or a tumour biopsy sample collected within 6 weeks prior to screening) as defined in the Laboratory Manual 7. Participants must have measurable disease as per RECIST 1.1 or evaluable disease. Lesions that will be subject to mandatory biopsy before, during, and after the dosing cannot be considered as TLs as per RECIST requirements. 8. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention. 1. Haemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment). 2. Absolute neutrophil count ≥ 1.5×109/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment). 3. Platelet count ≥ 100×109/L (platelet transfusion is not allowed within 1 week prior to screening assessment). 4. Serum albumin ≥ 2.5 g/dL. 5. TBL ≤ 1.5 × ULN or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinaemia). 6. Except in the setting of HBV, ALT and AST ≤ 2.5 × ULN; for participants with hepatic metastases, ALT and AST ≤ 5 × ULN. See Exclusion Criterion 8 for requirements in the setting of HBV. 7. Calculated CrCL ≥ 30 mL/min as determined by Cockcroft Gault (using actual body weight). 9. Male and/or female assigned at birth, inclusive of all gender identities. 10. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; (a) Male participants: (i) Use of a condom plus an additional contraceptive method, or avoid intercourse throughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd, in addition to the female partner using a highly effective contraceptive method. (ii) Starting at the time of first dose of Dato-DXd, male participants must not freeze or donate sperm at any time during this study and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of study intervention. (b) Female participants:Female participants not of child-bearing potential (ii) Female participants receiving HRT and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for WOCBP if they wish to continue using HRT during the study. Otherwise, HRT must be discontinued to allow confirmation of post-menopausal status prior to study enrolment; (iii) WOCBP must use one highly effective form of contraception or avoid intercourse throughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. All WOCBP must have a negative serum pregnancy test documented during screening. (iv) Starting at the time of first dose of Dato-DXd, female participants must not donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of study intervention. 11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this CSP. 12. All races, genders, and ethnic groups are eligible for this study. Exclusion Criteria: 1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases and ongoing or active infection), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol. 2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease. 3. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to Grade \> 2 for at least 3 months prior to the first dose of study intervention and managed with SoC treatment) which the investigator deems related to previous anticancer therapy): 1. Chemotherapy-induced neuropathy 2. Fatigue 3. Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies, which may include but are not limited to hypothyroidism/hyperthyroidism, Type I diabetes, hyperglycaemia, adrenal insufficiency, or adrenalitis; and skin hypopigmentation (vitiligo) Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss). 4. Spinal cord compression or brain metastases (unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 2 weeks prior to the first dose of study intervention). Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants must have recovered from the acute toxic effect of radiotherapy (eg, dizziness and signs of increased intracranial pressure). A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and the first dose of study intervention. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for CNS metastatic disease and the first dose of study intervention. 5. Leptomeningeal carcinomatosis or metastasis. 6. Has significant third-space fluid retention (eg, ascites or pleural effusion) and is not amenable for required repeated drainage. 7. Clinically significant corneal disease. 8. Has active or uncontrolled hepatitis B or C virus infection. Participants are eligible if they: 1. Have been curatively treated for HCV infection as demonstrated clinically and by viral serologies 2. Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis 3. Are HBsAg- and anti-HBc+ (ie, those who have cleared HBV after infection) and meet conditions i-iii of criterion 'd' below: 4. Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below: (i) HBV DNA viral load \< 2000 IU/mL (ii) Have normal transaminase values or, if liver metastases are present, abnormal transaminases, with a result of AST/ALT \< 3 × ULN, which are not attributable to HBV infection (iii) Start or maintain antiviral treatment if clinically indicated as per the investigator 9. Known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA

Inclusion Criteria: * (1) Type 2 diabetes diagnosed according to WHO diagnostic criteria, age ≥ 18 years old, ≤ 70 years old, gender unlimited (2) Diagnosed with NAFLD according to the criteria of the "Guidelines for the Prevention and Treatment of Non alcoholic Fatty Liver Disease (2018 Updated Edition)" (3) Before screening, patients with type 2 diabetes who were treated with single or combined drugs of stable dose (except TZDs, SGLT2i, GLP-1RA, insulin and GKAs) for ≥ 8 weeks and had poor blood glucose control, 7% ≤ HbA1c ≤ 10% (4)BMI≥24 kg/m2 (5) Can understand the content and methods of this study and voluntarily sign an informed consent form Exclusion Criteria: * (1) Patients with diabetes other than type 2 diabetes, including type 1 diabetes and gestational diabetes (2) Acute diabetes complications such as diabetes ketosis or ketoacidosis, diabetes hypertonic state, diabetes lactic acidosis or serious chronic diabetes complications (3) Individuals with a history of recurrent urinary tract infections and/or genital infections (as determined by clinical physicians) (4) Alcoholic liver disease (alcohol consumption equivalent to less than 30 g/d for males and less than 20 g/d for females in the past two years) (5) Exclude other liver diseases, such as chronic hepatitis B, chronic hepatitis C, primary cholestatic cirrhosis, ballistic obstructive diseases, drug-induced liver damage, hemochromatosis, hepatolenticular deformation, autoimmune hepatitis (6) Combined cirrhosis, combined liver cancer, HIV positive, drug abuse (7) Drugs (tamoxifen, amiodarone, sodium valproate, methotrexate, glucocorticoid, etc.), total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing's syndrome, β - lipoprotein deficiency, lipoatrophic diabetes, Mauriac syndrome, and other special conditions leading to fatty liver (8) Serious trauma or acute infection that may affect blood glucose control occurred within 4 weeks (9) Individuals who have experienced decompensated heart failure (NYHA grades III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or have undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within 6 months (10) There are obvious blood system diseases (such as aplastic anemia, myelodysplastic syndrome) or any diseases that cause hemolysis or red blood cell instability (such as malaria, hemolytic anemia) (11) Individuals with severe chronic gastrointestinal diseases, or those who have received treatment that may affect drug absorption (such as gastrointestinal surgery) (12) Uncontrolled hyperthyroidism (13) Individuals with mental or neurological disorders who are unwilling to communicate or unable to fully understand and collaborate (14) Pregnant or lactating women (15) There are any laboratory test indicators that meet the following standards: 1. Alanine aminotransferase\>2.0 times ULN and/or aspartate aminotransferase\>2.0 times ULN and/or total bilirubin\>2.0 times ULN 2. Blood ketones\>ULN 3. eGFR \<30ml/min/1.73 m2； Note: The formula for calculating eGFR is CKD-EPI (which can be calculated within the WeChat mini program) 4. Blood creatine kinase\>3 times ULN (16) In addition to the above, the researchers have determined that patients who are not suitable to participate in this clinical trial

Inclusion Criteria: * Adult ( \> 18 years old) hypertensive patients treated with RDN in France whatever the catheter and the indication. This might include retrospective data for patient already treated with RDN in the past. Exclusion Criteria: * RDN not proposed to the patient, patient opposing the collection and use of his/her data for research purposes.

Inclusion Criteria Uncontrolled Cohort: 1. The subject is male or female age 5 years and above 2. The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study 3. The subject has a diagnosis of asthma 4. The subject is willing and able to perform all study procedures 5. The subject must have uncontrolled asthma as defined by the presence on at least 2 days per week (can be non-consecutive days) in the 7 days prior to V1 of at least 3 symptoms from the following list: i. Cough ii. Wheezing iii. Shortness of breath iv. Chest tightness v. Nocturnal awakening with asthma vi. Limitation in activity due to asthma 6. The subject has a FeNO value based on the first measurement of at least 30 ppb if an adult or at least 25 ppb if \<18 years old measured on a cleared FeNO device (e.g., NIOX VERO®) Inclusion Criteria Controlled Cohort: 1. The subject is male or female age 5 years and above 2. The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study 3. The subject has an established diagnosis of asthma for at least 180 days prior to V1 4. The subject is willing and able to perform all study procedures Exclusion Criteria Uncontrolled: 1. The subject is in need of immediate referral to the emergency department 2. The subject has taken the following medications in the indicated period before V1: 1. OCS within 4 weeks 2. ICS within 2 weeks 3. Biologic therapies (e.g., omalizumab or dupilumab) within 12 weeks. Note: Use of as needed ICS+SABA is also exclusionary in the 2 weeks prior to V1 3. The subject has a contraindication to corticosteroids. 4. The subject has demonstrated significant non-compliance during a previous clinical trial 5. The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter 6. The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis 7. Subject is an employee/relative of the following: 1. Biometry Inc. 2. Contract Research Organization(s) running the study 3. Investigational Site 4. Study Vendors 8. Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study 9. A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco 10. Pregnant or nursing subjects Exclusion Criteria Controlled: 1. The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis 2. The subject has demonstrated significant non-compliance during a previous clinical trial 3. The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter. 4. Subject is an employee/relative of the following: 1. Biometry Inc. 2. Contract Research Organization(s) running the study 3. Investigational Site 4. Study Vendors 5. Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study 6. A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco 7. Pregnant or nursing subjects

Inclusion Criteria: * Moderate to severe open angle glaucoma (including POAG, PG, and PXG) * Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9 * Visual acuity HM or better * VF MD -6dB or worse * Failed medical therapy and/or laser treatment * Incisional glaucoma surgery contemplated as next intervention * Phakic or pseudophakic Exclusion Criteria: * Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma * Previous incisional glaucoma surgery * ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days * Active ocular inflammation or edema, clinically significant corneal dystrophy * Corneal or other pathology preventing accurate Goldmann applanation tonometry

Inclusion Criteria: 1. Signed and dated Informed Consent Form (ICF) obtained prior to any trial-specific screening procedure. 2. Patient is ≥ 18 years-old at the time of ICF signature. 3. Patient is female with known menopausal status at the time of initiation of adjuvant endocrine therapy (ET), or male. 4. Patient with histologically confirmed unilateral and unifocal primary invasive adenocarcinoma of the breast prior to initiating adjuvant chemotherapy, if indicated, or within 6 months of initiating adjuvant endocrine therapy if chemotherapy is not indicated. Patients who receive neoadjuvant endocrine therapy or chemotherapy are allowed to enroll. 5. Patient has breast cancer that is positive for ER and/or PR according to the local laboratory as determined on the most recently analyzed tissue sample. 6. Patient has HER2-negative breast cancer defined as a negative in situ hybridization test (FISH, CISH, or SISH) or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (ISH) test is required to confirm the HER2-negative status. 7. Patient has available archival tumor tissue from the diagnostic biopsy or surgical specimen, for submission to a central laboratory for Signatera testing (unless Signatera Genome clinical testing has already been performed). 8. Patient after surgical resection where tumor was removed completely (i.e., negative microscopic margins on final pathology) and have Anatomic Stage II that is either: * N1 or, * If N0, T2 or T3 with G2-3 and/or Ki67≥20% (testing for Ki67 not mandatory), excluding G1. Notes: 1. Patients who received neoadjuvant treatment must meet the criteria for stage, grade, Ki67 in any presurgical staging/sample and/or in the surgical specimen. 2. Categorization into the AJCC 8th edition Anatomic Stage Groups requires determination of the T, N and M categories. ALND can be omitted. 9. Patient has no contraindication to adjuvant ET and is planned to be treated with ET for 5 years (since enrollment date) or more. 10. Provider and patient must be agreeable to initiate CDK4/6 inhibitors only upon ctDNA detection. 11. Patient may have received up to 6 months of standard adjuvant ET at the time of enrollment and any amount of neoadjuvant endocrine therapy. 12. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 13. Patient must not have a clinical contraindication to ribociclib or abemaciclib. 14. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 15. Women of childbearing potential (CBP) must have a confirmed negative serum pregnancy test within 14 days prior to enrollment. 16. Women of reproductive potential should be advised of the potential risk of CDK4/6 inhibitors to a fetus, and use effective contraception during CDK 4/6 inhibitor therapy. Exclusion Criteria: 1. Patient has had prior exposure to a CDK4/6 inhibitor. 2. Patient is concurrently using hormone replacement therapy. 3. Patient with a known contraindication or hypersensitivity to ribociclib or abemaciclib as per the FDA indication label. 4. Patients with a multicentric and/or multifocal and synchronous contralateral breast cancer are ineligible. 5. Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. 6. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 5 years before ICF signature. Note: Patients with prior or concurrent in situ malignancies are eligible provided that adequate curative treatment is completed prior to enrollment. 7. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic antibacterial therapy, etc.) or limit life expectancy to ≤5 years. 8. Patient participated in another interventional study and received treatment with an investigational product (or used an investigational device) within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.

Inclusion Criteria: * Diagnosis of Arterial Hypertension (AH) in accordance with NICE guidelines. * Under pharmacological treatment for AH with antihypertensive drug, type and dose maintained for the previous four months. * Blood Pressure with values \<180 and \<110 mmHg for office systolic and diastolic BP, respectively. * Not currently engaged in any structured or supervised exercise training programme, including resistance, aerobic, or isometric exercise, defined as planned exercise performed ≥2 times per week at moderate or greater intensity, for at least three months prior to enrolment. * Written informed consent provided. Exclusion Criteria: * Body mass index \>35 kg/m2. * Presence of cardiovascular disease beyond hypertension. * Known orthopaedic, musculoskeletal, or neurological conditions that restrain isometric exercise execution. * Presence of secondary hypertension * Inability to follow verbal instructions or complete study protocol

Inclusion Criteria: * age 18 or older * foreign-born immigrant woman * self-reported history of cumulative exposure to violence, and presence of PTSD and/or depression symptoms Exclusion Criteria: * Participants who don't meet the above criteria

Inclusion Criteria: 1. Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects. 2. Adult males and females, ≥18 to ≤65 years of age (inclusive) at screening. 3. Diagnosis of T2DM of at least 7 years at the time of screening. 4. Must be receiving treatment with up to 3 antidiabetic agents (except insulin) at a stable, optimal, or maximum tolerated dose for at least 3 months prior to screening and with no dose changes expected during the study. 5. Must have HbA1c ≥7.5% and ≤9.5% at the screening visit. 6. Must have BMI ≥ 22.5 and ≤38.5 kg/m2 at the screening visit, with stable (± 5%) body weight within the previous 3 months of screening. 7. Female volunteers: 1. Must be of non-childbearing potential, i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle stimulating hormone \[FSH\] level consistent with postmenopausal status, per local laboratory guidelines), or 2. If of childbearing potential, must: i. Have a negative pregnancy test at the screening visit and on Day 1. ii. Agree not to attempt to become pregnant or donate ova from signing the informed consent form (ICF) until at least 33 days after the last dose of study drug. iii. Agree to use adequate contraception (defined as use of a condom by the male partner combined with use of a highly effective method of contraception) from one month prior to screening until at least 33 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle. 8. Male volunteers: 1. Must agree not to donate sperm from signing the ICF until at least 93 days after the last dose of study drug. 2. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception) from signing the ICF until at least 93 days after the last dose of study drug. 3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, must agree to use a condom from signing the ICF until at least 3 days after the last dose of study drug. 9. Have suitable venous access for blood sampling, as determined by the investigator (or delegate). 10. Willing and able to comply with all study assessments, including performing SMPG and completing a study diary, and adhere to the protocol schedule and restrictions. Exclusion Criteria: 1. Diagnosis of diabetes other than T2DM (e.g., type 1 diabetes, latent autoimmune diabetes of adults, monogenic diabetes, gestational diabetes) or at least one of the following at screening: 1. Fasting C-peptide \<0.8 ng/mL 2. Fasting insulin \>50 µIU/mL 2. Treatment with insulin within 3 months prior to or during screening. 3. Severe hypoglycaemia (defined as the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery), hypoglycaemia unawareness, diabetic ketoacidosis, or non-ketotic hyperosmolar state within 3 months of screening. 4. Use of weight loss agents (Section 21.2) or diet (hypocaloric diet), unless the diet or weight loss treatment (prescription, herbal, over-the-counter, or other) has been stopped at least 3 months prior to screening and the participant has had stable (± 5%) body weight within the previous 3 months of screening. 5. Chronic systemic corticosteroid use, defined as any daily dose \>10 mg prednisone or equivalent, for more than 2 consecutive weeks within 3 months prior to or during screening. Note: Topical, inhaled, ocular, nasal, or other non-systemic corticosteroid use is allowed. 6. Any use of hepatotoxic drugs (e.g., statins), gastric acid reducing medications, medications metabolized via the cytochrome P450 system (e.g., P-gp inhibitors, antifungal agents \[ketoconazole, itraconazole\], macrolides \[erythromycin, clarithromycin\], calcium channel blockers \[verapamil, diltiazem\], or medications with the potential for drug-drug interactions) within 3 months of screening. 7. Personal or family history (first-degree relative) of multiple endocrine neoplasia type 1. 8. History of or current acute or chronic pancreatitis or pancreatectomy. 9. History of or current liver cirrhosis, liver transplant, or any other liver disease including, but not limited to, the following: alcoholic liver disease, autoimmune or viral hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitryspin deficiency requiring treatment. Note: Metabolic dysfunction-associated liver disease/metabolic dysfunction associated steatohepatitis without portal hypertension or cirrhosis and with acceptable liver function test results, as determined by the investigator (or delegate), is not exclusionary. 10. Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the gastrointestinal tract (including weight-reducing surgery and procedures) that could affect the interpretation of study data, as determined by the Investigator (or delegate). Note: Appendectomy, hernia repair, cholecystectomy, and similar conditions, as determined by the investigator (or delegate), are not exclusionary. 11. Any of the following events or conditions within 3 months prior to or during screening: hospitalisation due to unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or significant cerebrovascular disease, or symptomatic heart failure (New York Heart Association Class III or IV). 12. Mean QT interval corrected using the Fridericia method (QTcF) \>450 msec for men and \>470 msec for women on screening ECG; or unstable, uncontrolled, or life-threatening arrhythmia or heart block, as assessed by the investigator (or delegate). 13. Untreated or unstable hypertension, defined as systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg after 10 minutes of supine rest and confirmed by repeated measurement at screening. Individuals with blood pressure above this threshold may have blood pressure-lowering medication(s) initiated and/or adjusted and be rescreened. 14. Any history of malignant disease in the last 5 years (excludes surgically resected squamous cell or basal cell carcinoma of the skin and cervical cancer in situ that have been treated with potentially curative therapy). 15. History of or current haemoglobinopathy (e.g., sickle cell anaemia, thalassaemia major, sideroblastic anaemia) or any other clinically important haematological abnormality (e.g., leucopoenia, thrombocytopaenia) as judged by the investigator (or delegate). 16. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness, within the past 3 months of screening, as determined by the investigator (or delegate) to be clinically relevant. 17. Any of the following laboratory abnormalities at screening: 1. Aspartate aminotransferase ≥1.5 × upper limit of normal range (ULN) 2. Alanine aminotransferase ≥1.5 × ULN 3. Alkaline phosphatase (ALP) ≥1.5 × ULN 4. Total bilirubin ≥1.5 × ULN (except for Gilbert's syndrome, which is not exclusionary, provided that direct (conjugated) bilirubin is ≤ ULN) 5. Haemoglobin \<11.5 g/dL (115 g/L) for males and \<10.5 g/dL (105 g/L) for females 6. Estimated glomerular filtration rate ≤60 mL/minute/1.73 m2 as de

Inclusion Criteria: * Pregnant or postpartum women aged 19 years or older * Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome * At risk for eclampsia and eligible for seizure prophylaxis * Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose. * Admitted or plan to proceed with delivery Exclusion Criteria: * \<32 weeks estimated gestational age * History of epilepsy or seizure disorders unrelated to pregnancy * Allergy or contraindication to Levetiracetam or Magnesium Sulfate * Severe renal impairment (Oliguria \<120ml in 4 hours) * Plan for neonatal comfort care

Inclusion Criteria: * Aged between 24 and 85 years of age inclusive (66% 24Y to 65Y; and 33% \>65Y to 85Y) * Diagnosed with T1D (made on clinical criteria) for at least 1 year * Insulin regimen either on MDI or insulin pump with at least 40% in one mode * Minimum total daily insulin dose 0.4 Units per kg / day (can be on insulin pump or MDI); * HbA1c \<10% (86mmol/ mol) * Minimum daily carbohydrate intake of 100g * Willing to adhere to the study protocol * Ability to perform high-intensity exercise (specific to the exercise sub-study) Exclusion Criteria: * Pregnancy or planned pregnancy * eGFR \<30ml/min/1.73m2 * History of DKA in the last 12 months * Use of low carbohydrate diet (\<100g/day) * Diabetic gastroparesis * Tape allergy * Heavy alcohol use (15 standard drinks per week or binge drinking) * Use of SGLT inhibitor in the last month * Medications increasing the risk of DKA e.g. steroids, anorectic agents (eg phentermine, naltrexone HCl/bupropion HCl, and GLP 1 agonists). * Major medical or psychiatric illness that in the opinion of the investigator would interfere with protocol adherence or impact participant safety.

Inclusion Criteria: 1. Seeking screening navigation services through programs at a participating site (Georgetown Lombardi Cancer Center or Helen F. Graham Cancer Center \& Research Institutes) 2. Eligible for breast cancer screening while also due and eligible for colorectal cancer screening (per USPSTF guidelines) 3. Female sex 4. Aged 45-74 5. Identify as Black/African American race and/or Hispanic/Latin(e)(a) ethnicity 6. Speak English or Spanish with enough fluency to complete study activities 7. Stated willingness to comply with all study procedures (navigation, surveys) and availability for the duration of the study 8. Provision of completed electronic informed consent form Exclusion Criteria: 1. Not engaged with or planning to use navigation programs at Georgetown Lombardi Cancer Center and Helen F. Graham Cancer Center \& Research Institute 2. Not eligible for breast cancer screening or not due and eligible for colorectal cancer screening (per USPSTF guidelines) 3. History of breast and/or colorectal cancer; or Reporting symptoms related to breast and/or colorectal cancer (e.g., GI bleeding, breast mass) 4. Male sex, Intersex, or other sex 5. Under age 45 or over age 74 6. Identifies as neither Black/African American race nor Hispanic/Latin(e)(a) ethnicity 7. Speaks neither English nor Spanish with enough fluency to complete study activities 8. Stated unwillingness to comply with study procedures (navigation, surveys) or unavailability for the duration of the study 9. Inability to provide electronic informed consent, or needing another person to authorize informed consent on their behalf

Inclusion Criteria: • inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL Exclusion Criteria: * having a planned discharge to a rehabilitation or nursing facility, * a contraindication to sensor placement, * if discharge is anticipated to be \>30 days post-transplant, or * if recent transplant also included a kidney or pancreas transplant

Inclusion Criteria: * Age ≥18 years * All patients enrolled in the program (high-risk and very high-risk patients) Exclusion Criteria: * Not able to provide informed consent * No access to smartphone and/or tablet * Inability to use digital tools required for the program